Immunogenic compositions comprising FIV and HIV gag antigens
The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.
1. An immunogenic composition comprising a) an FIV p24 protein, and b) an HIV-1 p24 protein, wherein said FIV p24 protein and/or said HIV-1 p24 protein comprises an epitope that is evolutionarily conserved between FIV and HIV-1 such that an antibody that binds to said FIV p24 epitope also binds to said HIV-1 p24 epitope, and wherein said immunogenic composition comprises an amount of said FIV p24 protein and said HIV-1 p24 protein effective to induce an immune response in an animal immunized with said immunogenic composition.
2. An immunogenic composition comprising a) an FIV p24 protein, and b) an HIV-1 p24 protein, wherein said FIV p24 protein and HIV-1 p24 protein each comprise an epitope that binds an antibody, and wherein said antibody binds to said epitope on said FIV p24 protein and said antibody also binds to said epitope on said HIV-1 p24 protein, and wherein said immunogenic composition comprises an amount of said FIV p24 protein and said HIV-1 p24 protein effective to induce an immune response in an animal immunized with said immunogenic composition.
3. The immunogenic composition according to claim 2 , wherein said FIV p24 protein comprises FIV protein from two or more different FIV subtypes.
4. The immunogenic composition according to claim 3 , wherein said two or more subtypes are subtype A and subtype D.
5. The immunogenic composition according to claim 2 , wherein said composition is a liquid solution, powder, suspension, tablet, pill, capsule, or sustained release formulation.
6. The immunogenic composition according to claim 2 , wherein said composition further comprises one or more of water, saline, dextrose, glycerol, or ethanol.
7. The immunogenic composition according to claim 2 , wherein said composition further comprises one or more of an emulsifying agent, a pH buffering agent, or an adjuvant.
8. The immunogenic composition according to claim 7 , wherein said adjuvant is aluminum hydroxide or muramyl dipeptide.
9. The immunogenic composition according to claim 2 , further comprising an adjuvant.